Moderna wants to extent its European footprint

According to the 10-year old biotech company local commercial presences are to be established in Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics. This follows the recent announcement of plans for four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.

"Europe has played a critical role in Moderna’s ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. After a decade of pioneering the development of our mRNA platform, I am proud of the growth we continue to achieve," said Stéphane Bancel, Chief Executive Officer of Moderna, whose company currently is the second largest COVID-19 vaccine supplier globally. "I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe."

In Europe Moderna has already established commercial subsidiaries in Italy, France, Germany, Spain, Switzerland, and the United Kingdom. Established in 2021, Moderna Poland hosts the Moderna International Business Services (MIBS) Center, which provides critical functions, including finance, pharmacovigilance, human resources, and digital services. Moderna Poland will also expand to provide commercial capabilities.

The expansion comes as the company continues to scale up the manufacturing and distribution of its COVID-19 vaccine while advancing other mRNA vaccine candidates and therapeutics. Moderna has several key manufacturing partnerships across Europe, including Lonza in Switzerland and the Netherlands, ROVI in Spain, and a French Recipharm subsisiary.

Moderna’s pipeline currently includes 25 are in clinical programs that include mRNA therapeutics and vaccines for infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases, Moderna’s four strategic pillars:

• Developing a pan-respiratory annual booster vaccine and continuously customizing it. A pan-respiratory annual single booster vaccine covering multiple viruses, such as COVID-19, Flu, and Respiratory Syncytial Virus, could create value for the healthcare system through compliance, convenience to the customer (one vs. three injections), and reduction in vaccine administration cost.
• Developing first-in-class vaccines against latent viruses for which there are no approved vaccines today including Epstein-Barr Virus (Phase 1), human immunodeficiency virus (Phase 1), and Cytomegalovirus (Phase 3)
• Developing therapeutics based on mRNA-encoded proteins across oncology, cardiovascular, auto-immune disorders, and rare genetic diseases
• Developing therapeutics based on mRNA-encoded gene-editing enzymes